Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    

MEDIVATION INC
Mes dernières consult.
Most popular
SummaryNewsCompany 
News SummaryMost relevantAll newsSector newsTweets

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2013 | 03:30pm CEST

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
2016 Drugmaker Sanofi hungry for deals after earnings beat
2016 MEDIVATION : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼..
2016DJPfizer Throws Out Plan to Split Into Two Companies
2016 FARUQI & FARUQI, LLP : Announces Filing of a Class Action Lawsuit Against Mediva..
2016 EXCLUSIVE - GW PHARMACEUTICALS HIRES : sources
2016 MEDIVATION SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces the Investigation..
2016 Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation,..
2016 Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale o..
2016 SHAREHOLDER UPDATE : Brodsky & Smith, LLC Announces an Investigation of The Boar..
2016 Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale o..
More news
News from SeekingAlpha
05/17 Vantage Point - Are Charities The Best Way To Pay For Costly Drugs?
04/10 Axovant Sciences announces appointment of Dr. David Hung as CEO and expansion..
03/06 BIOTECH FORUM DAILY DIGEST : Biotech Closes Above Resistance Levels. Icahn Getti..
02/10 BIOTECH FORUM DAILY DIGEST : Buyout Rumors On The Rise; Aratana Therapeutics' De..
02/03 Pfizer May Be Another IBM
Managers
NameTitle
David T. Hung President, Chief Executive Officer & Director
Kim D. Blickenstaff Chairman
Mohammad Hirmand Chief Medical Officer
Anne Bowdidge Senior Director-Investor Relations
Sandy Cooper Senior Vice President-Human Resources
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC0
GILEAD SCIENCES11.65%104 409
REGENERON PHARMACEUTICALS20.67%47 756
VERTEX PHARMACEUTICALS107.56%39 003
ACTELION23.24%29 757
GENMAB22.08%13 881